The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global 23-valent Pneumococcal Vaccine Market Research Report 2025
Synopsis
The global 23-valent Pneumococcal Vaccine market was valued at US$ 1440 million in 2023 and is anticipated to reach US$ 1938.4 million by 2030, witnessing a CAGR of 4.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for 23-valent Pneumococcal Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding 23-valent Pneumococcal Vaccine.
Report Scope
The 23-valent Pneumococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global 23-valent Pneumococcal Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the 23-valent Pneumococcal Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Sanofipasteur
CDIBP
Kexing Bio
Changsheng Bio-Technology
Huaan Science and Technology Innovation
Segment by Type
Single Dose Vial
Pre-filled Syringe
Segment by Application
Chronic Cardiovascular Disease
Chronic Lung Disease
Chronic Liver Disease
People Living with Hiv
Leukemia
Lymphoma
Multiple Myeloma
General Malignancy
Chronic Kidney Disease
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of 23-valent Pneumococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of 23-valent Pneumococcal Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global 23-valent Pneumococcal Vaccine market was valued at US$ 1440 million in 2023 and is anticipated to reach US$ 1938.4 million by 2030, witnessing a CAGR of 4.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for 23-valent Pneumococcal Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding 23-valent Pneumococcal Vaccine.
Report Scope
The 23-valent Pneumococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global 23-valent Pneumococcal Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the 23-valent Pneumococcal Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Sanofipasteur
CDIBP
Kexing Bio
Changsheng Bio-Technology
Huaan Science and Technology Innovation
Segment by Type
Single Dose Vial
Pre-filled Syringe
Segment by Application
Chronic Cardiovascular Disease
Chronic Lung Disease
Chronic Liver Disease
People Living with Hiv
Leukemia
Lymphoma
Multiple Myeloma
General Malignancy
Chronic Kidney Disease
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of 23-valent Pneumococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of 23-valent Pneumococcal Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 23-valent Pneumococcal Vaccine Market Overview
1.1 Product Overview and Scope of 23-valent Pneumococcal Vaccine
1.2 23-valent Pneumococcal Vaccine Segment by Type
1.2.1 Global 23-valent Pneumococcal Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Single Dose Vial
1.2.3 Pre-filled Syringe
1.3 23-valent Pneumococcal Vaccine Segment by Application
1.3.1 Global 23-valent Pneumococcal Vaccine Market Value by Application: (2024-2030)
1.3.2 Chronic Cardiovascular Disease
1.3.3 Chronic Lung Disease
1.3.4 Chronic Liver Disease
1.3.5 People Living with Hiv
1.3.6 Leukemia
1.3.7 Lymphoma
1.3.8 Multiple Myeloma
1.3.9 General Malignancy
1.3.10 Chronic Kidney Disease
1.3.11 Other
1.4 Global 23-valent Pneumococcal Vaccine Market Size Estimates and Forecasts
1.4.1 Global 23-valent Pneumococcal Vaccine Revenue 2019-2030
1.4.2 Global 23-valent Pneumococcal Vaccine Sales 2019-2030
1.4.3 Global 23-valent Pneumococcal Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 23-valent Pneumococcal Vaccine Market Competition by Manufacturers
2.1 Global 23-valent Pneumococcal Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global 23-valent Pneumococcal Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global 23-valent Pneumococcal Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global 23-valent Pneumococcal Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of 23-valent Pneumococcal Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of 23-valent Pneumococcal Vaccine, Product Type & Application
2.7 23-valent Pneumococcal Vaccine Market Competitive Situation and Trends
2.7.1 23-valent Pneumococcal Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest 23-valent Pneumococcal Vaccine Players Market Share by Revenue
2.7.3 Global 23-valent Pneumococcal Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 23-valent Pneumococcal Vaccine Retrospective Market Scenario by Region
3.1 Global 23-valent Pneumococcal Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global 23-valent Pneumococcal Vaccine Global 23-valent Pneumococcal Vaccine Sales by Region: 2019-2030
3.2.1 Global 23-valent Pneumococcal Vaccine Sales by Region: 2019-2024
3.2.2 Global 23-valent Pneumococcal Vaccine Sales by Region: 2025-2030
3.3 Global 23-valent Pneumococcal Vaccine Global 23-valent Pneumococcal Vaccine Revenue by Region: 2019-2030
3.3.1 Global 23-valent Pneumococcal Vaccine Revenue by Region: 2019-2024
3.3.2 Global 23-valent Pneumococcal Vaccine Revenue by Region: 2025-2030
3.4 North America 23-valent Pneumococcal Vaccine Market Facts & Figures by Country
3.4.1 North America 23-valent Pneumococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America 23-valent Pneumococcal Vaccine Sales by Country (2019-2030)
3.4.3 North America 23-valent Pneumococcal Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe 23-valent Pneumococcal Vaccine Market Facts & Figures by Country
3.5.1 Europe 23-valent Pneumococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe 23-valent Pneumococcal Vaccine Sales by Country (2019-2030)
3.5.3 Europe 23-valent Pneumococcal Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific 23-valent Pneumococcal Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific 23-valent Pneumococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific 23-valent Pneumococcal Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific 23-valent Pneumococcal Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America 23-valent Pneumococcal Vaccine Market Facts & Figures by Country
3.7.1 Latin America 23-valent Pneumococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America 23-valent Pneumococcal Vaccine Sales by Country (2019-2030)
3.7.3 Latin America 23-valent Pneumococcal Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa 23-valent Pneumococcal Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa 23-valent Pneumococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa 23-valent Pneumococcal Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa 23-valent Pneumococcal Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global 23-valent Pneumococcal Vaccine Sales by Type (2019-2030)
4.1.1 Global 23-valent Pneumococcal Vaccine Sales by Type (2019-2024)
4.1.2 Global 23-valent Pneumococcal Vaccine Sales by Type (2025-2030)
4.1.3 Global 23-valent Pneumococcal Vaccine Sales Market Share by Type (2019-2030)
4.2 Global 23-valent Pneumococcal Vaccine Revenue by Type (2019-2030)
4.2.1 Global 23-valent Pneumococcal Vaccine Revenue by Type (2019-2024)
4.2.2 Global 23-valent Pneumococcal Vaccine Revenue by Type (2025-2030)
4.2.3 Global 23-valent Pneumococcal Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global 23-valent Pneumococcal Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global 23-valent Pneumococcal Vaccine Sales by Application (2019-2030)
5.1.1 Global 23-valent Pneumococcal Vaccine Sales by Application (2019-2024)
5.1.2 Global 23-valent Pneumococcal Vaccine Sales by Application (2025-2030)
5.1.3 Global 23-valent Pneumococcal Vaccine Sales Market Share by Application (2019-2030)
5.2 Global 23-valent Pneumococcal Vaccine Revenue by Application (2019-2030)
5.2.1 Global 23-valent Pneumococcal Vaccine Revenue by Application (2019-2024)
5.2.2 Global 23-valent Pneumococcal Vaccine Revenue by Application (2025-2030)
5.2.3 Global 23-valent Pneumococcal Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global 23-valent Pneumococcal Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck 23-valent Pneumococcal Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Sanofipasteur
6.2.1 Sanofipasteur Corporation Information
6.2.2 Sanofipasteur Description and Business Overview
6.2.3 Sanofipasteur 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sanofipasteur 23-valent Pneumococcal Vaccine Product Portfolio
6.2.5 Sanofipasteur Recent Developments/Updates
6.3 CDIBP
6.3.1 CDIBP Corporation Information
6.3.2 CDIBP Description and Business Overview
6.3.3 CDIBP 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 CDIBP 23-valent Pneumococcal Vaccine Product Portfolio
6.3.5 CDIBP Recent Developments/Updates
6.4 Kexing Bio
6.4.1 Kexing Bio Corporation Information
6.4.2 Kexing Bio Description and Business Overview
6.4.3 Kexing Bio 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kexing Bio 23-valent Pneumococcal Vaccine Product Portfolio
6.4.5 Kexing Bio Recent Developments/Updates
6.5 Changsheng Bio-Technology
6.5.1 Changsheng Bio-Technology Corporation Information
6.5.2 Changsheng Bio-Technology Description and Business Overview
6.5.3 Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Product Portfolio
6.5.5 Changsheng Bio-Technology Recent Developments/Updates
6.6 Huaan Science and Technology Innovation
6.6.1 Huaan Science and Technology Innovation Corporation Information
6.6.2 Huaan Science and Technology Innovation Description and Business Overview
6.6.3 Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Product Portfolio
6.6.5 Huaan Science and Technology Innovation Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 23-valent Pneumococcal Vaccine Industry Chain Analysis
7.2 23-valent Pneumococcal Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 23-valent Pneumococcal Vaccine Production Mode & Process
7.4 23-valent Pneumococcal Vaccine Sales and Marketing
7.4.1 23-valent Pneumococcal Vaccine Sales Channels
7.4.2 23-valent Pneumococcal Vaccine Distributors
7.5 23-valent Pneumococcal Vaccine Customers
8 23-valent Pneumococcal Vaccine Market Dynamics
8.1 23-valent Pneumococcal Vaccine Industry Trends
8.2 23-valent Pneumococcal Vaccine Market Drivers
8.3 23-valent Pneumococcal Vaccine Market Challenges
8.4 23-valent Pneumococcal Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global 23-valent Pneumococcal Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global 23-valent Pneumococcal Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global 23-valent Pneumococcal Vaccine Market Competitive Situation by Manufacturers in 2023
Table 4. Global 23-valent Pneumococcal Vaccine Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global 23-valent Pneumococcal Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global 23-valent Pneumococcal Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global 23-valent Pneumococcal Vaccine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market 23-valent Pneumococcal Vaccine Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of 23-valent Pneumococcal Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of 23-valent Pneumococcal Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of 23-valent Pneumococcal Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of 23-valent Pneumococcal Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global 23-valent Pneumococcal Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in 23-valent Pneumococcal Vaccine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global 23-valent Pneumococcal Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global 23-valent Pneumococcal Vaccine Sales by Region (2019-2024) & (K Units)
Table 18. Global 23-valent Pneumococcal Vaccine Sales Market Share by Region (2019-2024)
Table 19. Global 23-valent Pneumococcal Vaccine Sales by Region (2025-2030) & (K Units)
Table 20. Global 23-valent Pneumococcal Vaccine Sales Market Share by Region (2025-2030)
Table 21. Global 23-valent Pneumococcal Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Region (2019-2024)
Table 23. Global 23-valent Pneumococcal Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Region (2025-2030)
Table 25. North America 23-valent Pneumococcal Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America 23-valent Pneumococcal Vaccine Sales by Country (2019-2024) & (K Units)
Table 27. North America 23-valent Pneumococcal Vaccine Sales by Country (2025-2030) & (K Units)
Table 28. North America 23-valent Pneumococcal Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America 23-valent Pneumococcal Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe 23-valent Pneumococcal Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe 23-valent Pneumococcal Vaccine Sales by Country (2019-2024) & (K Units)
Table 32. Europe 23-valent Pneumococcal Vaccine Sales by Country (2025-2030) & (K Units)
Table 33. Europe 23-valent Pneumococcal Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe 23-valent Pneumococcal Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific 23-valent Pneumococcal Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific 23-valent Pneumococcal Vaccine Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific 23-valent Pneumococcal Vaccine Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific 23-valent Pneumococcal Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific 23-valent Pneumococcal Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America 23-valent Pneumococcal Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America 23-valent Pneumococcal Vaccine Sales by Country (2019-2024) & (K Units)
Table 42. Latin America 23-valent Pneumococcal Vaccine Sales by Country (2025-2030) & (K Units)
Table 43. Latin America 23-valent Pneumococcal Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America 23-valent Pneumococcal Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa 23-valent Pneumococcal Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa 23-valent Pneumococcal Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa 23-valent Pneumococcal Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global 23-valent Pneumococcal Vaccine Sales (K Units) by Type (2019-2024)
Table 51. Global 23-valent Pneumococcal Vaccine Sales (K Units) by Type (2025-2030)
Table 52. Global 23-valent Pneumococcal Vaccine Sales Market Share by Type (2019-2024)
Table 53. Global 23-valent Pneumococcal Vaccine Sales Market Share by Type (2025-2030)
Table 54. Global 23-valent Pneumococcal Vaccine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global 23-valent Pneumococcal Vaccine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Type (2019-2024)
Table 57. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Type (2025-2030)
Table 58. Global 23-valent Pneumococcal Vaccine Price (US$/Unit) by Type (2019-2024)
Table 59. Global 23-valent Pneumococcal Vaccine Price (US$/Unit) by Type (2025-2030)
Table 60. Global 23-valent Pneumococcal Vaccine Sales (K Units) by Application (2019-2024)
Table 61. Global 23-valent Pneumococcal Vaccine Sales (K Units) by Application (2025-2030)
Table 62. Global 23-valent Pneumococcal Vaccine Sales Market Share by Application (2019-2024)
Table 63. Global 23-valent Pneumococcal Vaccine Sales Market Share by Application (2025-2030)
Table 64. Global 23-valent Pneumococcal Vaccine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global 23-valent Pneumococcal Vaccine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Application (2019-2024)
Table 67. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Application (2025-2030)
Table 68. Global 23-valent Pneumococcal Vaccine Price (US$/Unit) by Application (2019-2024)
Table 69. Global 23-valent Pneumococcal Vaccine Price (US$/Unit) by Application (2025-2030)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Merck 23-valent Pneumococcal Vaccine Product
Table 74. Merck Recent Developments/Updates
Table 75. Sanofipasteur Corporation Information
Table 76. Sanofipasteur Description and Business Overview
Table 77. Sanofipasteur 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Sanofipasteur 23-valent Pneumococcal Vaccine Product
Table 79. Sanofipasteur Recent Developments/Updates
Table 80. CDIBP Corporation Information
Table 81. CDIBP Description and Business Overview
Table 82. CDIBP 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. CDIBP 23-valent Pneumococcal Vaccine Product
Table 84. CDIBP Recent Developments/Updates
Table 85. Kexing Bio Corporation Information
Table 86. Kexing Bio Description and Business Overview
Table 87. Kexing Bio 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Kexing Bio 23-valent Pneumococcal Vaccine Product
Table 89. Kexing Bio Recent Developments/Updates
Table 90. Changsheng Bio-Technology Corporation Information
Table 91. Changsheng Bio-Technology Description and Business Overview
Table 92. Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Product
Table 94. Changsheng Bio-Technology Recent Developments/Updates
Table 95. Huaan Science and Technology Innovation Corporation Information
Table 96. Huaan Science and Technology Innovation Description and Business Overview
Table 97. Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Product
Table 99. Huaan Science and Technology Innovation Recent Developments/Updates
Table 100. Key Raw Materials Lists
Table 101. Raw Materials Key Suppliers Lists
Table 102. 23-valent Pneumococcal Vaccine Distributors List
Table 103. 23-valent Pneumococcal Vaccine Customers List
Table 104. 23-valent Pneumococcal Vaccine Market Trends
Table 105. 23-valent Pneumococcal Vaccine Market Drivers
Table 106. 23-valent Pneumococcal Vaccine Market Challenges
Table 107. 23-valent Pneumococcal Vaccine Market Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of 23-valent Pneumococcal Vaccine
Figure 2. Global 23-valent Pneumococcal Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global 23-valent Pneumococcal Vaccine Market Share by Type in 2023 & 2030
Figure 4. Single Dose Vial Product Picture
Figure 5. Pre-filled Syringe Product Picture
Figure 6. Global 23-valent Pneumococcal Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global 23-valent Pneumococcal Vaccine Market Share by Application in 2023 & 2030
Figure 8. Chronic Cardiovascular Disease
Figure 9. Chronic Lung Disease
Figure 10. Chronic Liver Disease
Figure 11. People Living with Hiv
Figure 12. Leukemia
Figure 13. Lymphoma
Figure 14. Multiple Myeloma
Figure 15. General Malignancy
Figure 16. Chronic Kidney Disease
Figure 17. Other
Figure 18. Global 23-valent Pneumococcal Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global 23-valent Pneumococcal Vaccine Market Size (2019-2030) & (US$ Million)
Figure 20. Global 23-valent Pneumococcal Vaccine Sales (2019-2030) & (K Units)
Figure 21. Global 23-valent Pneumococcal Vaccine Average Price (US$/Unit) & (2019-2030)
Figure 22. 23-valent Pneumococcal Vaccine Report Years Considered
Figure 23. 23-valent Pneumococcal Vaccine Sales Share by Manufacturers in 2023
Figure 24. Global 23-valent Pneumococcal Vaccine Revenue Share by Manufacturers in 2023
Figure 25. The Global 5 and 10 Largest 23-valent Pneumococcal Vaccine Players: Market Share by Revenue in 2023
Figure 26. 23-valent Pneumococcal Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 27. Global 23-valent Pneumococcal Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 28. North America 23-valent Pneumococcal Vaccine Sales Market Share by Country (2019-2030)
Figure 29. North America 23-valent Pneumococcal Vaccine Revenue Market Share by Country (2019-2030)
Figure 30. United States 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Canada 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Europe 23-valent Pneumococcal Vaccine Sales Market Share by Country (2019-2030)
Figure 33. Europe 23-valent Pneumococcal Vaccine Revenue Market Share by Country (2019-2030)
Figure 34. Germany 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. France 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. U.K. 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Italy 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Russia 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Asia Pacific 23-valent Pneumococcal Vaccine Sales Market Share by Region (2019-2030)
Figure 40. Asia Pacific 23-valent Pneumococcal Vaccine Revenue Market Share by Region (2019-2030)
Figure 41. China 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Japan 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. South Korea 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. India 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Australia 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. China Taiwan 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Indonesia 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Thailand 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Malaysia 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Latin America 23-valent Pneumococcal Vaccine Sales Market Share by Country (2019-2030)
Figure 51. Latin America 23-valent Pneumococcal Vaccine Revenue Market Share by Country (2019-2030)
Figure 52. Mexico 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Brazil 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Argentina 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Middle East & Africa 23-valent Pneumococcal Vaccine Sales Market Share by Country (2019-2030)
Figure 56. Middle East & Africa 23-valent Pneumococcal Vaccine Revenue Market Share by Country (2019-2030)
Figure 57. Turkey 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. Saudi Arabia 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 59. UAE 23-valent Pneumococcal Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 60. Global Sales Market Share of 23-valent Pneumococcal Vaccine by Type (2019-2030)
Figure 61. Global Revenue Market Share of 23-valent Pneumococcal Vaccine by Type (2019-2030)
Figure 62. Global 23-valent Pneumococcal Vaccine Price (US$/Unit) by Type (2019-2030)
Figure 63. Global Sales Market Share of 23-valent Pneumococcal Vaccine by Application (2019-2030)
Figure 64. Global Revenue Market Share of 23-valent Pneumococcal Vaccine by Application (2019-2030)
Figure 65. Global 23-valent Pneumococcal Vaccine Price (US$/Unit) by Application (2019-2030)
Figure 66. 23-valent Pneumococcal Vaccine Value Chain
Figure 67. 23-valent Pneumococcal Vaccine Production Process
Figure 68. Channels of Distribution (Direct Vs Distribution)
Figure 69. Distributors Profiles
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
